ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best stocks to buy in a rising market, according to Wall Street analysts. On April 9, ImmunityBio, Inc. (NASDAQ:IBRX) delivered impressive preliminary operational results for its fiscal quarter ending March 31, 2026.
Product revenue in the quarter was up 168% year over year to $44.2 million. The increase comes on the heels of ANKTIVA, an FDA-approved treatment for non-muscle invasive bladder cancer, commercial launch. The significant product revenue builds on 2025 net product revenue of $113 million, a 700% increase over 2024. ImmunityBio exited the quarter with $380.9 million in cash and cash equivalents.
ANKTIVA is the company’s lead product, expected to solidify its revenue base as it has been approved across five jurisdictions representing 34 countries. Its continued momentum underscores growing physician adoption and disciplined commercial execution. Following strong growth in 2025, ImmunityBio is focused on scaling in the US and expanding into global markets to pursue new revenue streams.
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company focused on developing and commercializing next-generation immunotherapies that activate a patient’s natural killer (NK) cells and T cells to treat cancers and infectious diseases. Its lead FDA-approved drug, ANKTIVA (N-803), is used in combination with BCG to treat non-muscle invasive bladder cancer (NMIBC).
While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 11 Best TSX Stocks to Buy According to Hedge Funds and 8 Best Australian Stocks to Buy in 2026.
Disclosure: None. Follow Insider Monkey on Google News.
